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(group 1 n¼17 and group 2 n¼15), which were compared to
matched historical controls (n¼54). We also performed a
retrospectively corrected analysis of steroid refractivity at
day 7 after start of corticosteroids in the different groups.
Group 1 received a median of 1 (range 1-5) infusion on
day 11 (range 1-31) after standard treatment compared to
group 2, who received a median of 2 infusions (range 1-4,
p<0.05) on day 6 (range 0-26, ns). No adverse events related
to the treatment were observed. At 4 weeks after treatment,
60% of the patients in group 1 had responded to the treat-
ment. In contrast, all patients in group 2 responded
(p<0.05). All patients in the treatment groups received
fungal prophylaxis.
The overall cumulative survival (OS) at 365 days was 78%
for group 2, as compared to 47% for group 1 and 28% for the
controls (p<0.001). When the groups were corrected for
steroid-refractivity, the OS was 76% for group 2, 38% for
group 1 and 6% for the controls (p<0.001). In the control
group, the risk of dying from GvHD was 51%, compared to
48% for group 1, whereas none of the three deceased patients
in group 2 died from GvHD (p<0.005). In the last 18 months,
no patients have died from acute GvHD at our center.
In conclusion, DSCs might be an effective treatment of
GvHD. The infusion should be prepared in albumin, given as
early as possible and in repeated doses. All patients should
receive fungal prophylaxis and should be closely monitored
for any infectious complications.Figure. Kaplan-Meier curve for the probability of relapse according to PIR-
CHE-I numbers. Patients presenting above median PIRCHE-I have a signiﬁ-
cantly reduced probability of relapse compared to those presenting lower
numbers of PIRCHE-I.510
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Introduction: Unrelated Cord Blood Transplantation (UCBT)
provides a curative therapy for patients with hematologicalmalignancies (and a variety of benign disorders). HLA-mis-
matched UCBT is associatedwith improved leukemia control.
The aim of this study was to investigate whether indirect
recognition of the mismatched HLA provides an explanation
for this improved graft-versus-leukemia (GVL) effect, and
can be used to identify donors with optimal GVL properties
without impacting probability on graft-versus-host disease
(GVHD).
Methods: All consecutive pediatric patients transplanted
from 2004 for various diseases after myeloablative condi-
tioning (either Busulfan-based or TBI-based), with an UCBT
were included. The probability of indirect recognition was
predicted by determining the number of Predicted Indirectly
ReCognizable HLA Epitopes (PIRCHE), as described previ-
ously (K. A. Thus, et al., BBMT 2014). Patients were divided
into two groups, according to the numbers of PIRCHE pre-
sented by HLA class I and II (PIRCHE-I and eII, respectively),
above and at or below median number of PIRCHE. Primary
endpoint: relapse. Secondary endpoints: acute- and chronic
GVHD, disease-free survival (DFS), and transplant-related
mortality (TRM). Cox proportional hazard models were used
for analyses.
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included; 50 for a malignancy; 22 AML, 22 ALL, and 6 other.
127 (81%) patients received Bu-based and 29 (19%) TBI-based
conditioning. In multivariate analyses, above median num-
ber PIRCHE-I were associated with lower probability of
relapse (HR 0.139, p¼0.006, Fig 1), and a trend for improved
disease-free survival (HR 0.411, p¼0.086). This effect was not
present for PIRCHE-II. In the whole cohort, PIRCHE-I or eII
were neither associated with acute-GVHD grade II-IV (HR
0.747, p¼0.466, HR 1.263, p¼0.554) nor extensive chronic
GVHD (HR 1.502, p¼0.671, HR 3.420, p¼0.293), nor TRM (HR
1.753, p¼0.198, HR 0.991, p¼0.983, for PIRCHE-I and eII
respectively).
Conclusion: High numbers of PIRCHE-I lead to improved
GVL effects after UCBT, while GVHD was not impacted by the
number of PIRCHE. PIRCHE may provide an additional tool
for individualized donor selection to improve survival
chances. The effects observed in this study need to be vali-
dated in other cohorts.
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Introduction: Chronic graft-versus-host-disease (cGvHD) is
a late complication (>90 days) after allogeneic hematopoi-
etic stem cell transplantation (HSCT). Symptomsmight occur
inmultiple organs and vary frommild to severe. In this study,
the NIH criteria were used to group the patients. We per-
formed an extensive immune-phenotypic analysis using cells
and plasma from patients diagnosed with and without
cGvHD. The aim of the study is to gain information on
possible markers that could be used by clinicians to aid in the
diagnosis of cGvHD.
Methods: Peripheral blood samples were obtained from
patients  1 year post-HSCT with an acute GvHD no higher
than grade I. Patients were divided into 4 groups: no
(N¼10), mild (N¼6), moderate (N¼5) and severe cGvHD
(N¼8). Cytokine levels were measured by Luminex and an
immune-phenotypic analysis was done by multicolor ﬂow
cytometry. Univariate analysis comparing the different
patient groups was done with the Mann-Whitney
U test.
Results: Due to usage of immunosuppressive treatments in
the moderate and severe cGvHD groups, we chose to
compare patients with no versus mild cGvHD and moderateTable
Factors associated with day 28 CR/PR and 6-month NRM
Factor N OR of CR/PR (95% CI
Second Line Rx
ATG* 50 1.0
MMF 28 2.1 (0.7-6.8)
Boost 25 1.9 (0.5-7.6)
Other 10 0.2 (0.02-2.2)
GVHD Risk Score (at 2nd Rx)
Standard* 55 1.0
High 58 0.3 (0.1-0.9)
Time from Onset to 2nd Rx
214 days* 63 1.0
>14 50 0.3 (0.1-1.0)versus severe cGvHD. Expression of the cell activation
marker CD38 was higher on total T cells and CD8+ T cells
(p¼0.005 for both subsets) in mild cGvHD patients compared
to patients without cGVHD. Furthermore, severe cGvHD pa-
tients had higher levels of CD8+ Tcells (p¼0.03) than patients
with moderate cGvHD. Additionally, several Th2-associated
cytokines were down regulated in severe cGvHD patients,
compared to the other patient groups. An analysis was also
done based on the presence of cGvHD in speciﬁc organs
(lung, mouth and skin) within the moderate and severe
cGvHD group. In patients with lung cGvHD; both the
expression of degranulation marker CD107a (p¼0.003) on T
cells and the expression of KIR receptor CD158b on NK cells
negative for the Fc receptor CD16 (p¼0.035) were found to be
lower. Anti-inﬂammatory cytokine IL-10 was decreased
(p¼0.018) in patients with mouth cGvHD. Lastly, CD158b+
CD16+ NK cells and total CD158b+ NK cells were found to be
less frequent in patients with skin cGvHD (p¼0.017 for both
subsets).
Discussion: Mild and severe cGvHD patients appear to
have a more activated and cytotoxic immune-phenotype
compared to patients with no and moderate cGvHD,
respectively. Additionally, patients with speciﬁc organ-
oriented cGvHD seem to have a lower percentage of NK
cell subsets. In conclusion, it appears that patients with an
increasing severity of cGvHD have a more activated
cytotoxic phenotype, which seems to mostly depend on
CD8+ T cells and not on NK cells. By studying the
phenotype of the immune system in these cGvHD pa-
tients, we can gain new insights in the pathogenesis
behind cGvHD. Our ﬁndings, i.e. distorted immune cell
phenotypes, could potentially be used as biomarkers in
the diagnostics of cGvHD.512
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Background: Steroid-refractory acute graft-versus-host
disease (SR-aGVHD) remains the major, non-relapse obstacle
to successful hematopoietic cell transplantation (HCT).
Evolving donor and cell sources, conditioning regimens and
GVHD prophylaxis are altering the ﬁeld of HCT. We evaluated) P RR of NRM (95% CI) P
1.0
0.20 0.5 (0.2-1.1) 0.07
0.36 0.2 (0.1-0.6) <0.01
0.19 0.4 (0.1-1.1) 0.08
1.0
0.04 1.0 (0.5-1.7) 0.89
1.0
0.05 1.2 (0.6-2.6) 0.57
